Lenalidomida Combix

Lenalidomide, the active ingredient in Lenalidomida Combix, is an immunomodulatory agent (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers and related disorders, particularly in adult patients who require disease‑modifying therapy. GNH USA supplies Lenalidomida Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal cell growth and immune dysregulation. - Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and corrects cytopenias. - Mantle cell lymphoma: contributes to disease control when combined with other agents in relapsed settings.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to easy bruising. - Diarrhea: loose stools that may require hydration. - Rash: mild skin eruptions or itching. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound immune suppression with fever. - Severe thrombocytopenia: risk of serious bleeding. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome: severe skin reaction requiring urgent care. - Hepatic failure: marked liver enzyme elevation and dysfunction.

Lenalidomide requires careful monitoring and specific safety measures. - Pregnancy: contraindicated; teratogenic risk mandates effective contraception for both sexes. - Blood counts: regular CBC monitoring to detect neutropenia or thrombocytopenia. - Thromboembolism risk: assess need for prophylactic anticoagulation in high‑risk patients. - Renal/hepatic impairment: dose adjustment may be needed based on organ function. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lenalidomide may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase drug exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin): additive bleeding potential. - Live vaccines: reduced efficacy and possible infection. - Other immunomodulatory agents: may amplify immunosuppression.